Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Lowered to $113.00 at UBS Group

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price objective reduced by UBS Group from $117.00 to $113.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a "neutral" rating on the specialty pharmaceutical company's stock. UBS Group's target price would indicate a potential upside of 7.53% from the stock's previous close.

A number of other research analysts also recently issued reports on JAZZ. Stifel Nicolaus increased their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a report on Friday, March 15th. Truist Financial reiterated a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. StockNews.com upgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, June 27th. Finally, Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a "buy" rating on the stock in a research report on Thursday, June 20th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $188.62.

Jazz Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ:JAZZ traded down $1.38 during midday trading on Tuesday, hitting $105.09. The company had a trading volume of 402,575 shares, compared to its average volume of 694,030. Jazz Pharmaceuticals has a 12 month low of $103.01 and a 12 month high of $146.70. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.64 and a beta of 0.58. The company has a current ratio of 2.27, a quick ratio of 1.90 and a debt-to-equity ratio of 1.38. The firm has a fifty day simple moving average of $108.89 and a 200 day simple moving average of $116.55.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The business had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. On average, analysts predict that Jazz Pharmaceuticals will post 15.35 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company's stock, valued at approximately $4,016,369.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 4.20% of the company's stock.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after buying an additional 116 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in Jazz Pharmaceuticals by 26.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 115,308 shares of the specialty pharmaceutical company's stock valued at $13,938,000 after acquiring an additional 23,768 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in shares of Jazz Pharmaceuticals by 45.3% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 161,388 shares of the specialty pharmaceutical company's stock valued at $19,434,000 after acquiring an additional 50,300 shares during the period. Virtu Financial LLC grew its holdings in shares of Jazz Pharmaceuticals by 31.8% during the 1st quarter. Virtu Financial LLC now owns 11,696 shares of the specialty pharmaceutical company's stock worth $1,408,000 after purchasing an additional 2,819 shares in the last quarter. Finally, Plato Investment Management Ltd acquired a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth $228,000. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.